Dominique Bluteau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dominique Bluteau has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Adela Cañete
Hospital Universitario y Politècnico La Fe, 46026 Valencia, Spain
16 shared publications - Alba Rubio-San-Simón
Hospital Infantil Universitario Niño Jesús
16 shared publications - Amaury Leruste
Institut Curie
16 shared publications - Arnaud Petit
Hôpital Armand Trousseau, APHP Sorbonne Université Paris France
16 shared publications - Aroa Soriano
Childhood Cancer and Blood Disorders Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
16 shared publications - Birgit Geoerger
Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
16 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (31)
ZMAT3 alleviates cell death in Fanconi anemia via adaptation of sphingolipid metabolism
Fanconi anemia (FA) is characterized by defective DNA repair and chronic p53 activation, predisposing to acute myeloid leukemia through persistent genomic instability. The molecular adaptations enabling cell survival under chronic stress remain poorly understood. This study investigates the role of ZMAT3, a p53 responsive RNA binding protein overexpressed in FA deficient cells, to elucidate its role in cellular adaptation. Using FA patient fibroblasts and Fancg KO mouse models, we launched transcriptomic profiling, lipidomic, and functional analyses. RNA-seq and lipidomic analyses revealed unexpected alterations in sphingolipid metabolism upon ZMAT3 depletion, linked to ceramide accumulation and downregulation of ASAH1 (acid ceramidase). Functionally, ZMAT3 depletion increased DNA damage and enhanced ferroptosis susceptibility, an iron dependent cell death mechanism. Mechanistically, our results showed that ZMAT3 promotes ASAH1 expression, limits ceramide accumulation and protects cells from ferroptosis induced death which could participate to preleukemic clonal evolution and pointing to areas for further exploration in FA-associated malignancies.
- 31 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (31)
Open AccessZMAT3 alleviates cell death in Fanconi anemia via adaptation of sphingolipid metabolism
Fanconi anemia (FA) is characterized by defective DNA repair and chronic p53 activation, predisposing to acute myeloid leukemia through persistent genomic instability. The molecular adaptations enabling cell survival under chronic stress remain poorly understood. This study investigates the role of ZMAT3, a p53 responsive RNA binding protein overexpressed in FA deficient cells, to elucidate its role in cellular adaptation. Using FA patient fibroblasts and Fancg KO mouse models, we launched transcriptomic profiling, lipidomic, and functional analyses. RNA-seq and lipidomic analyses revealed unexpected alterations in sphingolipid metabolism upon ZMAT3 depletion, linked to ceramide accumulation and downregulation of ASAH1 (acid ceramidase). Functionally, ZMAT3 depletion increased DNA damage and enhanced ferroptosis susceptibility, an iron dependent cell death mechanism. Mechanistically, our results showed that ZMAT3 promotes ASAH1 expression, limits ceramide accumulation and protects cells from ferroptosis induced death which could participate to preleukemic clonal evolution and pointing to areas for further exploration in FA-associated malignancies.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels of Arm D and Probabilities of Toxicity at the End of Dose Escalation (n=24 Patients Evaluable for DLT) and after the Whole Study (n=65 Patients Evaluable for DLT)
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels of Arm D and Probabilities of Toxicity at the End of Dose Escalation (n=24 Patients Evaluable for DLT) and after the Whole Study (n=65 Patients Evaluable for DLT)
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Somatic Driver Mutations (A), Focal Amplification/deletions (B) or Gene Fusions (C) and Germline Mutations (D) Detected in 65 Patients Explored in the Molecular Analysis.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Somatic Driver Mutations (A), Focal Amplification/deletions (B) or Gene Fusions (C) and Germline Mutations (D) Detected in 65 Patients Explored in the Molecular Analysis.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Representativeness of Study Participants
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Representativeness of Study Participants
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Treated in Arm D.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Treated in Arm D.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels for Dose Escalation
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels for Dose Escalation
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Pharmacogenetic Study Evaluating the Association Between 5 Genetic Variants and Dose-limiting Toxicity (DLT) (N=41).
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Pharmacogenetic Study Evaluating the Association Between 5 Genetic Variants and Dose-limiting Toxicity (DLT) (N=41).
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Objective Response Rates in 66 Patients Treated Overall and per Dose Escalation or Dose Expansion in Other Malignancies and Ewing Sarcoma.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Objective Response Rates in 66 Patients Treated Overall and per Dose Escalation or Dose Expansion in Other Malignancies and Ewing Sarcoma.